Palbociclib and an anti-PD-1 antibody treatment significantly prolonged overall survival compared to single medication treatments in mouse models of cancer, which supports the idea that immune-checkpoint antagonists and CDK4/6 inhibitors should be combined to create a more potent anticancer medicine. This evidence concerns the gene CDK4 and cancer.